These collective observations suggest that selective LMP7 inhibition may represent a feasible pharmacological approach for reshaping the TME of TNBC/IBC in a manner permissive to CD8+ T cell-mediated immune surveillance. Here, CD8A is linked to inflammatory breast carcinoma.